whether angiotensin receptor blockers increase cancer or cardiovascular risk
August 2010
See updated FDA information regarding ARBs/cancer and Olmesartan/CV risks
ARBs and cancer. A recent analysis suggests that ARBs are associated with a small increased risk of cancer...about 1 more case for every 143 patients using an ARB instead of placebo for 4 years.
One theory is that angiotensin might be involved in cell growth. ARBs increase free angiotensin by blocking its receptors.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 200+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote